Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study

Joseph A. Sparano, Anatoly N. Makhson, Vladimir F. Semiglazov, Sergei A. Tjulandin, Olga I. Balashova, Igor N. Bondarenko, Natalia V. Bogdanova, George M. Manikhas, Gennadiy P. Oliynychenko, Valery A. Chatikhine, Sen H. Zhuang, Liang Xiu, Zhilong Yuan, Wayne R. Rackoff

Research output: Contribution to journalArticlepeer-review

94 Scopus citations

Fingerprint

Dive into the research topics of 'Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study'. Together they form a unique fingerprint.

Medicine & Life Sciences